In October 2022, the FDA launched the "Total Product Life Cycle Advisory Program (TAP)" pilot to accelerate the development of innovative medical devices and technologies critical to public health. TAP facilitates "early, frequent, and strategic communication" with the FDA to enhance collaboration with manufacturers and third parties, speeding up patient access to innovative medical devices.
